Johnson Chemical Pharmaceutical Works Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Johnson Chemical Pharmaceutical Works şirketinin toplam hissedar öz sermayesi NT$1.7B ve toplam borcu NT$149.7M olup, bu da borç-öz sermaye oranını 8.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$1.9B ve NT$261.5M dir. Johnson Chemical Pharmaceutical Works 'in FAVÖK'ü NT$96.7M faiz karşılama oranı -9.5 dur. Şirketin NT$1.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

8.9%

Borç/özkaynak oranı

NT$149.73m

Borç

Faiz karşılama oranı	-9.5x
Nakit	NT$1.05b
Eşitlik	NT$1.68b
Toplam yükümlülükler	NT$261.50m
Toplam varlıklar	NT$1.95b

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Feb 18

Recent updates

Could Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Have The Makings Of Another Dividend Aristocrat?

Mar 25

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Feb 18

Weak Financial Prospects Seem To Be Dragging Down Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Stock

Feb 01

Estimating The Fair Value Of Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747)

Jan 12

Is Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) An Attractive Dividend Stock?

Dec 25

Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Growing Earnings But Are They A Good Guide?

Dec 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4747 'nin kısa vadeli varlıkları ( NT$1.3B ) kısa vadeli yükümlülüklerini ( NT$171.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4747 şirketinin kısa vadeli varlıkları ( NT$1.3B ) uzun vadeli yükümlülüklerini ( NT$89.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4747 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4747 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 8.9% seviyesine yükseldi.

Borç Kapsamı: 4747 'nin borcu işletme nakit akışı ( 55.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 4747 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Johnson Chemical Pharmaceutical Works Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.47 (vs NT$0.46 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.75 in 2Q 2023)

Now 20% overvalued

Upcoming dividend of NT$1.50 per share

First quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.74 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$2.24 (vs NT$2.16 in FY 2022)

New minor risk - Market cap size

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 24, 2024

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: NT$0.45 (vs NT$0.64 in 3Q 2022)

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: NT$0.75 (vs NT$0.48 in 2Q 2022)

New minor risk - Market cap size

Investor sentiment improves as stock rises 26%

Upcoming dividend of NT$2.00 per share at 2.5% yield

Investor sentiment improves as stock rises 17%

First quarter 2023 earnings released: EPS: NT$0.75 (vs NT$0.42 in 1Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: NT$2.16 (vs NT$1.64 in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

No independent directors

Third quarter 2022 earnings released: EPS: NT$0.64 (vs NT$0.44 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.48 (vs NT$0.43 in 2Q 2021)

Upcoming dividend of NT$1.45 per share

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.35 in 1Q 2021)

No independent directors

Full year 2021 earnings released: EPS: NT$1.64 (vs NT$2.12 in FY 2020)

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 26, 2022

Third quarter 2021 earnings released: EPS NT$0.44 (vs NT$0.47 in 3Q 2020)

Upcoming dividend of NT$1.92 per share

First quarter 2021 earnings released: EPS NT$0.35 (vs NT$0.61 in 1Q 2020)

Could Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Have The Makings Of Another Dividend Aristocrat?

Full year 2020 earnings released: EPS NT$2.12 (vs NT$2.15 in FY 2019)

New 90-day high: NT$37.65

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 17, 2021

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Weak Financial Prospects Seem To Be Dragging Down Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Stock

New 90-day low: NT$36.80

Estimating The Fair Value Of Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747)

Is Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) An Attractive Dividend Stock?

Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Growing Earnings But Are They A Good Guide?

Third quarter 2020 earnings released: EPS NT$0.47

New 90-day low - NT$37.55

New 90-day low - NT$38.10

First half earnings released

New 90-day low - NT$39.00

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin